Targeted IgMs agonize ocular targets with extended vitreal exposure

Treatment of ocular disease is hindered by the presence of the blood-retinal barrier, which restricts access of systemic drugs to the eye. Intravitreal injections bypass this barrier, delivering high concentrations of drug to the targeted tissue. However, the recommended dosing interval for approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yvonne, Paluch, Maciej, Zorn, Julie A., Rajan, Sharmila, Leonard, Brandon, Estevez, Alberto, Brady, John, Chiu, Henry, Phung, Wilson, Famili, Amin, Yan, Minhong, Ciferri, Claudio, Matsumoto, Marissa L., Lazar, Greg A., Crowell, Susan, Hass, Phil, Agard, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577241/
https://www.ncbi.nlm.nih.gov/pubmed/32936727
http://dx.doi.org/10.1080/19420862.2020.1818436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577241/
https://www.ncbi.nlm.nih.gov/pubmed/32936727
http://dx.doi.org/10.1080/19420862.2020.1818436

Ejemplares similares